Your browser doesn't support javascript.
loading
Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
Journal of Lipid and Atherosclerosis ; : 32-41, 2018.
Article Dans Coréen | WPRIM | ID: wpr-714786
ABSTRACT
In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes. Since 2008, three CVOTs that have studied dipeptidyl peptidase-4 (DPP-4) inhibitors and four CVOTs of a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) have been reported. Each of the completed CVOTs showed the noninferiority of respective drugs to placebo for primary CV composite endpoint. Among them, liraglutide and semaglutide showed a reduction of major adverse cardiovascular events. However, the mechanisms for the observed cardiovascular differences between DPP-4 inhibitors and GLP-1RA, and across individual GLP-1RA are not clearly understood. Therefore, this review will summarize the CVOTs of the DPP-4 inhibitors and GLP-1RA, interpretation of cardioprotective results of incretin-based therapy and the possible mechanism of action.
Sujets)

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Food and Drug Administration (USA) / Diabète de type 2 / Glucagon-like peptide 1 / Inhibiteurs de la dipeptidyl-peptidase IV / Incrétines / Liraglutide / Hypoglycémiants Type d'étude: Essai clinique contrôlé / Guide de pratique langue: Coréen Texte intégral: Journal of Lipid and Atherosclerosis Année: 2018 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Food and Drug Administration (USA) / Diabète de type 2 / Glucagon-like peptide 1 / Inhibiteurs de la dipeptidyl-peptidase IV / Incrétines / Liraglutide / Hypoglycémiants Type d'étude: Essai clinique contrôlé / Guide de pratique langue: Coréen Texte intégral: Journal of Lipid and Atherosclerosis Année: 2018 Type: Article